Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD) - Concepedia

Concepedia

Publication | Closed Access

Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

76

Citations

35

References

2014

Year

Laura Pérez‐Martínez, Patricia Pérez‐Matute, Javier Aguilera‐Lizarraga, Susana Rubio-Mediavilla, Judit Narro, Emma Recio, Laura Ochoa‐Callejero, José A. Oteo, José Ramón Blanco

Journal of Antimicrobial Chemotherapy

Abstract

Maraviroc ameliorates hepatic steatosis in an experimental model of NAFLD.

References

	Year	Citations

Page 1